Improved therapeutic outcome following combination immunogene vaccination therapy in XXXX @entity1582 .

@entity2304 @entity19 @entity8271 @entity5 @entity24817 @entity1582
Increasing evidence suggests a role for immunologic vaccination and therapy in the management of minimal residual @entity1582 . We have previously demonstrated a synergistic effect of combining the Th1 stimulating cytokine IL-12 with the co-stimulatory molecule @entity8271 in @entity19 @entity1582 vaccination therapy. We reasoned that the efficacy of such treatment might be further improved by incorporating additional gene products which enhance the function of antigen presenting cells. Studies were therefore conducted with @entity19 @entity1582 BM1 cells expressing @entity24817 (membrane bound or soluble forms) or @entity2304 and the IL-12 x @entity8271 combination. Single agent and combined therapeutic approaches were explored. All gene-modified BM1 cells, except BM1/IL-12 x @entity8271 , developed @entity5 when subcutaneously injected into BALB/c @entity19 . As prophylactic @entity5 vaccines, the combined use of gene-modified BM1/sFlt3L+ @entity2304 +IL-12 x @entity8271 was most effective, providing 100% protection against subsequent parental BM1 @entity5 challenge. By comparison, only partial protection was observed with any single gene-engineered @entity5 vaccine. Notably, IL-12 x @entity8271 coexpressing BM1 cell vaccines were the most effective therapeutic vaccine in a minimal disease model. Such protective vaccination was achieved by stimulation of lymphocyte proliferation and enhancement of cytotoxic lymphocyte activity.
